CancerSELECT™ 125 analyzes the regions of a targeted panel of 125 well-characterized cancer genes. Matched tumor/normal or tumor samples are prepared using proprietary methods that accommodate low abundance, poor quality sample DNA. Combined with a proprietary capture design and high coverage next-generation sequencing, tumor-specific (somatic) mutations, copy number variations, microsatellite instability (MSI) and translocations are identified with a high sensitivity and specificity.
| CancerSELECT™ 125 Sequencing Key Metrics | |
|---|---|
| Regions Analyzed | Coding regions of 117 genes and selected regions of 41 genes |
| Sequencing Method | Illumina next generation sequencing |
| Bioinformatics | Patented PARE, Digital Karyotyping and VariantDx |
| Assay Sensitivity | >99% |
| Assay Specificity | >99.9999% |
| Sequencing Coverage | 1,250x |
| Turn-around Time | 2-3 weeks |
| Sample Requirements | Tumor only or tumor and matched normal (optimal results) |
| Sample Types | Frozen tumor or FFPE, cell lines, blood, saliva, and xenograft |
| DNA Input Required | 1ÎĽg (minimum 50ng) |
CancerCOMPLETE® utilizes exome capture to selectively analyze only the coding regions of the genome, allowing the coding regions, the “exome,” to be sequenced at high coverage. Using the tumor tissue and matched normal sample, this allows for the reliable identification of sequence mutations and copy number alterations. Additionally, regions frequently mutated in cancer (125 genes included in the CancerCOMPLETE® tests) are analyzed at high coverage to identify point mutations, copy number alterations, rearrangements and microsatellite instability (MSI).
| CancerCOMPLETE® Key Metrics | |
|---|---|
| Regions Analyzed | Coding regions of >20,000 genes and selected regions of 24 genes |
| Sequencing Method | Illumina next generation sequencing |
| Bioinformatics | Proprietary methods and visual inspection |
| Assay Sensitivity | >95% |
| Assay Specificity | >99.99% |
| Sequencing Coverage | 150x |
| Turn-around Time | 6 weeks (rush available) |
| Sample Requirements | Matched tumor and normal specimens (Blood or saliva) |
| Sample Types | Frozen tumor, FFPE, cell lines, blood, saliva, and xenograft |
| DNA Input Required | 1 µg (minimum 50 ng) |
| Minimum Tumor Cellularity | >70% |
PlasmaSELECT™ analyzes circulating tumor DNA for genetic alterations in cancer, eliminating the need for an invasive biopsy or tumor tissue. PlasmaSELECT™ may also be used to evaluate subclonal mutations in tumor tissue, when available. PlasmaSELECT™ evaluates a targeted panel of 64 well-characterized cancer genes. Cell-free DNA is extracted from plasma and prepared using proprietary methods that accommodate low abundance sample DNA. Samples are processed using a proprietary capture process and high coverage next-generation sequencing to allow tumor-specific (somatic) mutations and translocations to be identified with a high sensitivity and specificity. Analyses for sequence mutations, rearrangements or microsatellite instability (MSI) can be performed together or separately, depending on the specific alterations of interest.
| PlasmaSELECT™ Key Metrics | |
|---|---|
| Regions Analyzed | 64 Genes |
| Sequencing Method | Illumina next-generation sequencing |
| Bioinformatics | Patented PARE, Digital Karyotyping and VariantDx |
| Turn-around Time | 2-3 weeks |
| Sample Requirements | Whole blood or plasma |
| Sample Input Required | Two 10 ml tubes of peripheral whole blood; 6-10 ml plasma collected according to PGDx sample preparation instructions (>1-2ml for RUO) |
©2017 Personal Genome Diagnostics, Inc. All Rights Reserved.
